Tuesday 20 October 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

115.09 1.84 +1.62%

Follow INCY

Alert me

Market cap: $23.0B
P/E: 13.9×
Fwd P/E: 58.4×
Dividend yield: —
F-score: 9/9
Altman Z: 8.57
Beneish M: −2.43
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Incyte Corporation (INCY) Price to free cash flow

Alert me on Price to free cash flow

As of 19 October 2026, Incyte Corporation (INCY) trades at a price to free cash flow of 12.0×. Over the past ten years it has ranged from 0.0× (September 2024) to 956× (November 2024); the current reading is higher than 23% of that period. That is below the Biotechnology industry median of 21.8× and below the Healthcare sector median of 20.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/INCY/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Incyte Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/INCY/metrics/price-to-free-cash-flow">Incyte Corporation (INCY) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	14.5×	(76.16%)
FY2024	60.8×	86.60%
FY2023	32.6×	64.67%
FY2022	19.8×	(30.44%)
FY2021	28.5×	—
FY2020	0.0×	—
FY2019	29.7×	(42.29%)
FY2018	51.4×	—
FY2017	0.0×	—
FY2016	104×	(66.08%)

Period	Price to free cash flow	Change
Jun 2026	12.0×	(9.01%)
Mar 2026	13.2×	(8.94%)
Dec 2025	14.5×	2.41%
Sep 2025	14.2×	1.34%
42 more quarters	Free account

Against its own ten years

Low 0.0× High 956×

Ten-year median 26.4×

Current reading's percentile 23

Company	Price to free cash flow
GMAB Genmab A/S Sponsored ADR compare	n/m
INSM Insmed, Inc. compare	n/m
ROIV Roivant Sciences Ltd. compare	n/m
INCY Incyte Corporation	12.0×
EXEL Exelixis, Inc. compare	13.6×
RPRX Royalty Pharma PLC compare	20.5×
ALNY Alnylam Pharmaceuticals, Inc. compare	38.0×
ASND Ascendis Pharma A/S compare	38.2×
BNTX BioNTech SE Sponsored ADR compare	45.2×
Biotechnology industry median	21.8×
Healthcare sector median	20.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Incyte Corporation (INCY) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on INCY

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on INCY

Stockrow Weekly